Estriol may ease menopause-related cognitive decline
Women reported improvement across 6 cognitive domains during 12 months of estriol-based treatment, while murine models suggested a potential astrocyte-mediated mechanism.
By
Andrea Surnit
September 3, 2026
Clinical Scorecard: Estriol may ease menopause-related cognitive decline
At a Glance
Category Detail
Condition Menopause-related cognitive decline Key Mechanisms Estriol treatment may improve cognitive function via estrogen receptor beta signaling in brain cells. Target Population Menopausal women experiencing cognitive decline. Care Setting Standard patient care in a clinical setting.
Key Highlights
20 menopausal women with cognitive decline participated in the study. Participants received oral estriol daily for 12 months. Significant improvements were observed in cognitive symptoms across all assessed domains. No randomization or placebo group was included in the study. Cognitive changes were self-reported rather than measured through objective testing. Guideline-Based Recommendations
Diagnosis
Cognitive symptoms assessed using the Voskuhl Menopause Brain Fog Assessment. Management
Consider estriol-based hormone treatment for menopausal women with cognitive decline. Monitoring & Follow-up
Monitor cognitive symptoms and overall health during treatment. Risks
Caution advised due to lack of randomization and small sample size. Patient & Prescribing Data
Menopausal women aged around 53.5 years.
Estriol doses varied (2 mg, 4 mg, 8 mg) and were individualized.
Clinical Best Practices
Evaluate cognitive symptoms in menopausal women. Consider individualized hormone therapy based on clinical need. Encourage further research into estriol's effects on cognition. Related Resources & Content
